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New evidence has highlighted that miRNA production and trafficking can be dysregulated 
in both autoimmmune and neurological disorders. Multiple sclerosis (MS) in particular is 
an autoimmune pathology leading to neurodegeneration. Profiling studies performed on 
cells derived from MS patients have described a dysregulated network of miRNAs in 
both immune and neural cells. Interestingly, new evidence has emerged showing that 
circulating miRNAs are also dysregulated in MS body fluids, including plasma/serum and 
cerebrospinal fluid. This review summarizes the current scientific theories on the function 
of this altered circulating miRNA network. It builds up new insights about miRNA transfer 
mechanisms including extracellular vesicle trafficking involved in cell-to-cell communi-
cation and the possible physiopathological functions of these transfers in MS. Finally, 
this review proposes that monitoring altered miRNA expression levels could serve as a 
potential biomarker read-out of MS subtype and severity.
Keywords: multiple sclerosis, relapses, circulating miRNAs, extracellular vesicles, inflammation, demyelination, 
exosomes, biomarkers
iNTRODUCTiON
Multiple sclerosis (MS) is a human lymphocyte-mediated autoimmune disease affecting the central 
nervous system (CNS). Neurodegeneration of the CNS is associated with both neuron demyelination 
and inflammation in the so-called active lesions. It is common to separate relapsing–remitting MS 
(RRMS), in which periods of relapses (attacks) alternate with periods of remission, from primary 
progressive MS (PPMS) characterized by a constant worsening of CNS condition and minor remis-
sions. In about 60% of RRMS cases, the disease secondarily turns into a progressive form (secondary 
progressive or SPMS). miRNAs are small non-coding RNAs of about 20 nucleotides inhibiting the 
expression of their mRNA targets through degradation and/or by stopping mRNA translation (1). In 
most cases, they are transcribed by polymerase II into a stem–loop primary miRNA (pri-miRNA). 
The pri-miRNA is cleaved in the nucleus by a complex, including the RNase III Drosha, forming a 
pre-miRNA, which is exported into the cytosol thanks to Exportin 5. The cytosolic pre-miRNA is 
then cleaved by the endoribonuclease Dicer and associates with the RNA-induced silencing complex 
(RISC), which mediates mRNA translational silencing/degradation [reviewed in Ref. (2)].
Abbreviations: BBB, brain blood barrier; CNS, central nervous system; CSF, cerebrospinal fluid; EAE, experimental autoim-
mune encephalomyelitis; EV, extracellular vesicle; MRI, magnetic resonance imaging; MV, microvesicle; MVBs, multivesicular 
bodies; OND, other neurological diseases; RISC, RNA-induced silencing complex.
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The expression of miRNAs in MS was first assessed in cells 
derived either from MS patients’ blood samples or from active 
lesions (3, 4). Interestingly, a deregulated expression of certain 
cellular miRNAs has been proposed as a putative trigger in 
MS physiopathology (3, 5). In particular, miRNA regulation of 
disease-associated proinflammatory lymphocyte Th17 differen-
tiation has been actively investigated (3, 5–7). miR-21, miR-20b, 
and miR-326 were shown to regulate Th17 differentiation by 
modulating the expression of pivotal transcription factors of T cell 
differentiation [SMADs (6), STATs (7), RORγ (7), and Ets-1 (3)]. 
In this context and as miRNAs initially identified as cellular can 
be dysregulated in circulating fluids as well, interesting questions 
are raised regarding the potential functions of circulating miRNA 
in MS physiopathology. The expression of circulating miRNAs 
in body fluids, including serum and cerebrospinal fluid (CSF), 
of MS patients was indeed investigated in recent studies (8). In 
this review, “circulating miRNAs” refers to all cell-free miRNAs.
Using a combination of established methods of miRNA 
profiling, it is now possible to propose a provisional network 
of dysregulated miRNAs in MS. These approaches provide new 
insights and raise some interesting issues: how are disrupted 
cellular and circulating miRNA networks related together? What 
could be the role of circulating miRNAs in MS physiopathol-
ogy? Which molecular vectors carrying circulating miRNAs 
would be the most relevant to study and could these vectors be 
miRNA-associated actors of MS pathogenesis? This review first 
recapitulates the up-to-date network of dysregulated circulating 
miRNAs in MS patients. Second, extracellular vesicles (EVs) are 
considered as miRNA vectors and are proposed to be involved in 
miRNA-mediated pathogenesis. Finally, circulating miRNAs are 
proposed to be convenient, reliable, and accurate biomarkers to 
differentiate MS subtypes and evaluate MS severity.
Review
Dysregulated Network of Circulating 
miRNAs in MS Patient Fluids
Junker and colleagues have described the first miRNA profiling 
analysis performed on MS patient brain lesions in 2009 (4). 
Exponential number of publications was consecutively released 
focusing on miRNA profiling on different blood fractions, 
including immune cells and plasma fluid. In this review, the term 
“plasma” will be used interchangeably to describe serum and/or 
plasma. It aims at simplifying the view of circulating miRNAs, 
although serum and plasma certainly have different miRNA 
contents.
The main approach of miRNA profiling analyses is based on 
a microarray analysis in combination with quantitative PCR. 
But because the process of RNA extraction toward profiling 
is not standardized, caution is required when comparing two 
different analyses. Results strongly depend indeed on RNA 
extraction, miRNA quantification, and interpretation strate-
gies mainly based on the kind of internal control and statistical 
analysis that have been used. For instance, dealing with miRNA 
quantification, two important studies used the miRCURRY 
LNA™ Universal RT microRNA PCR kit from Exiqon (9, 10). 
It is based on SYBR green incorporation during qPCR per-
formed in 384 well plates, each containing different miRNA-
specific primers. On the other hand, miRNA quantification 
by Siegel and colleagues (11) was based on the incorporation 
of aminoallyls in mRNAs produced via the transcription of 
miRNA-derived cDNA (Amino Allyl MessageAmp™ II aRNA 
amplification kit from Life Technologies). Such differences in 
the procedure for miRNA profiling lead to massive variability. 
Researchers now aim at standardizing these techniques to 
comprehend profiling metadata (12). Interestingly, a next-
generation sequencing (NGS) technique was recently used to 
assess miRNA dysregulation in MS patients and confirmed the 
microarray analyses showing identical regulation of the eight 
miRNAs, which were previously found to be dysregulated (13). 
A previous study using the NGS technique also identified 43 
miRNAs that were dysregulated in immune-activated lymph 
nodes of experimental autoimmune encephalomyelitis (EAE)-
susceptible rats (14). In NGS technologies based on RNA 
sequencing (RNA-seq), the read counts of each miRNAs allow 
to estimate their relative expression level. RNA-seq has been 
shown to provide results with higher sensitivity and broader 
dynamic range as compared to microarray analyses (15, 16). 
Nevertheless, microarrays are still the most common technique 
to conduct miRNA profiling experiments for both financial and 
practical reasons. NGS outputs are massive and lack standard-
ized/user-friendly pipelines for processing and analyzing the 
data (17). However, as sequencing nucleotides gets cheaper and 
as new pipelines are being developed, we can expect NGS to 
become the predominant tool for monitoring miRNA levels.
Microarray analyses of MS patients’ whole blood (plasma and 
cells) or plasma have been extensively used to assess miRNA 
expression levels (5, 9–11, 13, 18, 19). As a result, a significant 
amount of data about circulating miRNA dysregulation in MS 
patients compared to healthy controls has been generated, sup-
plementing an already complex dataset of dysregulated miRNAs 
in immune cells and in the CNS. We applied a systematic search 
of miRNAs that have been shown to be deregulated in plasma 
(5, 9–11, 18), immune cells [B (20–22) or T cells (3, 22–26)], or the 
CNS (astrocytes, oligodendrocytes, brain endothelial cells, whole 
brain lesions, and whole brain) (4, 27–30). As a result, we collected 
19 studies that had generated microarray profiling metadata and 
filtered out the miRNAs that were not significantly deregulated 
in these microarrays. The significance of miRNA dysregulation is 
based on the statistical tests performed in the microarray studies 
themselves. We then compared the list of dysregulated miRNAs 
in each compartment side by side and highlighted the commonly 
dysregulated miRNAs between immune cells and plasma or 
between the CNS and plasma (Figure 1).
Our systematic search revealed that at least 62 miRNAs have 
already been shown to be significantly deregulated in plasma of MS 
patients, among which a majority was upregulated (54  miRNAs). 
A significant number of miRNAs were commonly dysregulated 
between plasma and immune cells (15 over a total of 160 miR-
NAs) and between plasma and the CNS (15 over a total of 118 
miRNAs) (Figure 1). The role of such a diagram is to draw atten-
tion on some miRNAs for further comprehensive and functional 
analyses. The finding of specific miRNAs deregulated in several 
FiGURe 1 | Overlapping between dysregulated miRNAs in plasma and lymphocytes or in plasma and the CNS of MS patients. Dysregulated miRNAs 
from plasma and lymphocytes (left panel) or from plasma and the CNS (right panel) were either identical (overlapping area) or not (single area). Data were compiled 
from miRNA profiling studies performed on plasma (5, 9–11, 18), immune cells [B (20–22) or T cells (3, 22–26)], and the CNS (astrocytes, oligodendrocytes, brain 
endothelial cells, whole brain lesions, and whole brain) (4, 27–30). Briefly, we selected dysregulated miRNAs from microarray profiling studies, filtered out miRNAs 
with non-significant variation of the expression level, and highlighted commonly dysregulated miRNAs. All overlapping miRNAs are listed and those written in white 
color are dysregulated in at least three compartments, including plasma and the CNS; miR, miRNA.
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compartments could help deciphering the compartment-specific 
role of miRNAs and help finding the interactions between these 
compartments. Interestingly, miR-221 is upregulated in both 
plasma (9) and Treg cells (24), whereas miR-221 is downregu-
lated in B cells (20) (Figure 1). In mature dendritic cells (DCs), 
miR-221 upregulation has been associated with increased levels 
of p27kip1 driving apoptosis (31). Also, miR-221 upregulation in 
T cells has been shown to inhibit survival and proliferation (32).
We suggest that commonly dysregulated miRNAs should be 
prioritized for functional assays in a cell-specific context. For 
instance, miR-23a, miR-223, miR-22, miR-326, and miR-21 
expressions are altered in at least three different compartments, 
including plasma and the CNS (Figure 1). Additional evidence 
to select putative miRNAs involved in MS pathogenesis include 
(i) the degree of deregulation observed (e.g., fold change as com-
pared to the control), (ii) a validation by RT-qPCR, and (iii) at 
least one demonstrated mRNA target. Thus, focusing on mi-326 
would be of particular interest, as its expression is drastically 
altered in CD4+ T cells (eightfold) (3), in active brain lesions 
(ninefold) (4), and in plasma (twofold) (5) and as it has been 
shown to target Ets-1, a negative regulator of Th17 differentiation 
(3). By contrast, although miR-22 expression is altered in three 
different compartments, it is with low fold change (4, 11, 24) and 
miR-22 has no defined but only predicted targets, including the 
B cell translocation gene 1 (BTG1), a regulator of cell prolifera-
tion, and the estrogen receptor alpha (ESRα) (11).
Finding the miRNAs that are differentially expressed in dif-
ferent compartments enables to prioritize miRNAs for functional 
involvement in MS pathogenesis, but it also aims at understanding 
the functional distribution of a given miRNA in different compart-
ments. It remains a complicated task since among the 30 miRNAs 
commonly dysregulated in plasma and another compartment, 
about one-third were upregulated in one compartment when 
downregulated in another one. miR-15a, a putative trigger of the 
regulation of CD4+ T cell apoptosis (23), well illustrates the com-
plexity of miRNA dysregulation: miR-15a has been highlighted 
downregulated in whole blood (19), B cells (20), CD4+ T cells (23), 
and brain endothelial cells from brain lesions (27) but upregulated 
in regulatory T cells (24) and active brain lesions (4). It remains 
unclear why the same miRNA would be differently deregulated 
between plasma and another compartment. This observation 
could be assigned to a lack of standardization in RNA extraction 
and quantification protocols leading to heterogeneous results. But 
one can speculate that a difference in miRNA levels between the 
inner (cellular) and outer part (extracellular) of the cell is a result 
of a selective process of miRNA release. In fact, major hypotheses 
involve apoptosis or mechanisms driving miRNA release into 
circulation. The latter will be further discussed considering the 
mechanisms triggering miRNA release.
extracellular vesicles as Potential vectors 
for Circulating Dysregulated miRNAs
The question of how dysregulated miRNAs are carried into MS 
patient fluids has not been addressed yet. However, extracellular 
miRNAs have already been identified with different carriers, 
including EVs (33). EVs can be distinguished based on their 
origin, size, and membrane markers. Among the different 
type of EVs, miRNAs were shown to be carried by exosomes, 
microvesicles (MVs), or apoptotic bodies mainly (Figure  2). 
Exosomes range between 50 and 100 nm, similar in size to viral 
or lipoprotein particles. They are formed by budding into the 
FiGURe 2 | Major pathways for extracellular vesicle biogenesis and for miRNA incorporation into exosomes. (1) The exosomal pathway includes MVB 
formation, exosome budding into MVB lumen, and exocytosis-mediated exosomal release. (a) Ubiquitinated RISC- and ESCRT-dependent incorporation of miRNAs 
into exosomes: model from Gibbings and colleagues (35). (b) Main pathway of miRNA biogenesis detailed in the Section “Introduction.” (2) The microvesicular 
pathway: miRNA uptake by microvesicles remains to be clarified. (3) The apoptotic pathway: apoptotic cells release apoptotic bodies containing fragment of the 
nucleus and putative miRNAs.
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lumen of multivesicular bodies (MVBs), important intermediates 
in the endolysosomal pathway, and are released by exocytosis of 
MVBs. Exosomes display different RNA profiles compared to 
cellular ones, suggesting a selective and active incorporation 
of miRNAs (34). A recent study highlighted that this selective 
and active incorporation of miRNAs into exosomes could be 
dependent on RISC and endosomal sorting complexes required 
for transport (ESCRT) (35). RISC and ESCRT are canonically 
involved in miRNA-mediated translation inhibition and bud-
ding processes, respectively. Further investigation is required to 
determine how these pivotal complexes regulate miRNA release 
and whether this regulation could drive differences between 
cellular and extracellular miRNA levels. The second category of 
EVs is MVs, which are 100–1000 nm particles directly budding 
from the plasma membrane. miRNAs are also found in MVs 
(36), but the mechanism by which they are incorporated is not 
yet elucidated. Apoptotic bodies are often much larger, from 1 to 
5 μm. Methods to isolate and characterize them are lacking, and 
most studies perform coculture with apoptotic cells (33). Recent 
data, however, suggest that miRNAs can be carried by endothelial 
cell-derived apoptotic bodies (37).
Otherwise, some studies highlighted protein-associated 
circulating miRNAs. Arroyo and colleagues described human 
blood extracellular miRNAs associated with a RISC unit called 
Ago2 (38). It is premature to draw conclusions about knowing 
whether this observation is physiological or not. Indeed, an 
active mechanism of protein-associated miRNA release has not 
been described yet. These miRNA–Ago2 complexes could also 
derive from dead cells or derive from an artifact through vesicle 
degradation  during miRNA purification. In fact, it is known that 
miRNA–Ago2 complexes are found in exosomes (8). Depending 
on culture conditions and cells used, extracellular miRNAs have 
also been described associated with RNA-binding protein nucle-
ophosmin (NPM1) (39) or bound to HDLs (40). Mechanisms by 
which the release is possible still remain unknown.
Evidences are in favor of EVs for being the main vectors of 
circulating miRNAs. Indeed, mechanisms of miRNA release into 
EVs have been largely described, whereas pathways leading to 
extracellular protein-associated miRNAs are poorly understood. 
But how miRNA-associated EVs could be implicated in MS 
pathogenesis? First, EVs were shown to be upregulated in the 
blood of MS patients compared to healthy controls (41). Thus, a 
difference in EV production could participate in establishing the 
dysregulated network of circulating miRNAs. Second, EVs have 
been implicated in MS pathogenesis (42), without a demonstrated 
role of miRNAs, but through associated protein factors that medi-
ate brain blood barrier (BBB) disruption. And finally, EVs are 
currently emerging as critical actors in cell-to-cell communica-
tion. It appears that a complex network of circulating miRNAs 
actually coexist with a complex network of EVs. Emerging results 
unveil that many different cells produce different types of EVs 
(Table 1). Among these cells, B cells, T cells, and neural cells were 
shown to be involved in MS pathogenesis. It was highlighted that 
B cells, Th1, Th17, regulatory T cells, brain endothelial cells, and 
monocytes produce not only exosomes but also MVs. DCs, B and 
T cells, and monocytes were shown in vitro (by coculture or EV 
addition) or sometimes in vivo to be recipient for EVs. In the CNS, 
neural cells, including glia cells, also exchange EVs (referenced 
TABLe 1 | emerging network of extracellular vesicles involving immune and brain cells as producing and recipient cells.
ev producing cells Type of evs ev receiving cells In vivo In vitro Reference
eva CoCb
EBV-infected B cells Exosome Monocyte-derived DC Yes Yes Yes (34)
B cells Exosome No No No No (44)
CMV-infected endothelial Exosome Blood CD4+ T cells No Yes Yes (45)
Brain endothelial cells Microvesicle Monocytes No Yes No (46)
GM-CSF-induced DCs Exosome CD8+ T cells No Yes Yes (47)
Migratory DCs Not defined Lymph node-resident CD8+ T cells Yes No No (48)
GM-CSF-induced DCs Microvesicle No No No No (49)
Blood T cells Exosome No No No No (50)
Regulatory T cells Exosome T and B cells, DCs No Yes Yes (44)
Th1 and Th17 cells Exosome No No No No (44)
THP-1 monocytic cells Microvesicle No No No No (51)
Microglia Microvesicle Hippocampal neurons No Yes No (52)
Oligodendrocyte Exosome-like Oligodendrocyte No Yes No (53)
Astrocyte Exosome Spinal neurons No Yes Yes (54)
aDirect addition of EVs on recipient cell.
bCellular coculture (CoC) between producing and recipient cells.
Colors depict: human-derived, mouse-derived, and rat-derived cells.
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in Table 1). Recently, immune cells were shown to transfer genetic 
information to brain cells in vivo (43). This transfer is likely to 
happen through EVs as purified EVs contained the genetic probe. 
Moreover, this genetic transfer was increased under peripheral 
inflammatory conditions. Peripheral inflammation and BBB 
disruption in MS pathology are two factors that could explain a 
passage of EVs from the CNS to the blood. It is also of interest to 
establish whether immune cells invading the CNS of MS patients 
could produce, locally in the CNS, EVs.
It has been demonstrated that many miRNAs are functionally 
involved in MS pathogenesis when their expression is altered. 
Determining the role of circulating miRNAs requires consider-
ing their carrier. In the following section, we propose cellular 
mechanisms describing the carrier-dependent effects of some 
circulating miRNAs on MS pathogenesis.
Potential Role of Circulating miRNAs 
in MS Pathogenesis
Experimental autoimmune encephalomyelitis is a mouse 
 (sometimes monkey or rat) autoimmune model aiming at 
 reproducing MS pathology features. It is now accepted that in 
both MS and its EAE model, pathogenesis involves lymphocytes 
including B cells (55), Th17 and Th1 cells (56) specific to myelin 
antigens. Production of these myelin-specific lymphocytes 
should require a primary migration of myelin-associated DCs 
and transfer of free antigens from the CNS to peripheral lymph 
nodes leading to the Th1/Th17 and B cell response, respectively 
(Figure  3). Migration of these cells into the CNS through a 
porous BBB participates to both inflammation in active lesions 
and axon demyelination.
The implication of cellular miRNAs in MS and EAE patho-
genesis is currently strongly investigated. In order to define the 
new concepts about circulating miRNA function, it is necessary 
to consider different elements: (i) producing and recipient cells 
for EVs, (ii) cellular and extracellular miRNA dysregulation, and 
(iii) cellular miRNAs functionally involved in MS/EAE. Some 
miRNA function and distribution seem relevant to suggest circu-
lating miRNA implication in Th17-mediated, Th1-mediated, and 
brain-resident cell-mediated MS pathogenesis (Figure 3).
miR-326
miR-326 is upregulated in CNS active lesions (4) and circulating 
CD4+ T cells (3) of MS patients. A study from Du and colleagues 
(3) on EAE mice demonstrated that miR-326 targets Ets-1, 
a negative regulator of Th17 differentiation, thus promoting 
Th17 differentiation. Their in vivo experiments highlighted that 
downregulation of miR-326 leads to an improved EAE score 
through inhibition of Th17 differentiation, whereas miR-326 
overexpression drives to a more severe EAE through Th17 dif-
ferentiation. Besides, it is known that Th17 produce exosomes 
(44), T cells receive EVs (Table 1) and that circulating miR-326 is 
upregulated in MS patients (5). Thus, it may be worth considering 
a cell non-autonomous effect of circulating miR-326: Th17 cells 
may indeed produce exosomes containing increased amount of 
miR-326 driving an amplification of Th17 differentiation through 
EV transfer between T cells (Figure 3).
miR-155
Of most studied miRNAs, miR-155 is a master miRNA implicated 
in MS and EAE, because its action is on both immune and brain 
cells. Indeed, miR-155−/− mice display a defective T cell develop-
ment and are resistant to EAE (57). miR-155 promotes Th17 and 
Th1 differentiation in EAE mice leading to inflammation and 
demyelination (5, 57). Moreover, miR-155 has been shown to be 
FiGURe 3 | Functions of dysregulated cellular and circulating miRNAs in MS/eAe physiopathology. Myelin-derived peptides reach the lymph node as free 
autoimmune-prone antigens or associated with antigen-presenting cells. It results in B cell and T cell activation and migration of these cells across a porous brain 
blood barrier. Unbalanced differentiation toward proinflammatory T cell subsets Th1 and Th17 is amplified by cellular miR-155 and miR-326 upregulation and by cell 
non-autonomous transfer of these miRNAs between T cells through putative EVs. In the CNS, miR-155 participates to microglia-mediated inflammation/
neurodegeneration. Brain inflammation is also aggravated by miR-155-mediated decrease of CD47, driving vulnerability of neural cells (evidence being for 
astrocytes) toward microglia-mediated phagocytosis. miRNAs are depicted as red dashes. EVs appear in the color of the producing cell and contain a single 
effective miRNA for simplification. HEV, high endothelial venules.
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upregulated in MS patient plasma (5). As Th1 and Th17 produce 
exosomes (Table 1) (44), a cell non-autonomous effect of circulat-
ing miR-155 could also amplify Th1 and Th17 differentiation thus 
increasing MS pathogenesis (Figure 3). Moreover, several studies 
have demonstrated that miR-155 is upregulated in MS brain white 
matter lesions (4), especially in microglia (28). miR-155 upregu-
lation in microglia promotes its activation, which is detected in 
part through proinflammatory cytokine secretion (28). miR-155 
upregulation in active lesions of MS patients also correlates with 
a decreased level of CD47, a transmembrane protein, which has 
been shown to dampen microglia activation, acting as a “don’t 
eat me” signal when induced on microglia neighboring cells 
(4). In vitro, CD47 has been highlighted as a target for miR-155 
(4). Thus, miR-155 upregulation drives macrophage activation 
intrinsically but also indirectly by reducing CD47 expression in 
astrocytes and oligodendrocytes (4). This process would then be 
partially responsible for inflammation and neurodegeneration 
through phagocytic processes (Figure 3). Eventually as microglia, 
astrocytes and oligodendrocytes produce EVs (Table  1), one 
could consider that upregulation of miR-155 in one of these cell 
types could be sufficient to upregulate miR-155 in the other cells 
in a cell non-autonomous manner (Figure  3). However, these 
results were obtained for single miRNA analyses. Combining 
functional effects of miRNAs increases the complexity to inter-
pret results. In fact, one study highlighted that regulatory T cells 
produce exosomes containing both miR-155 and let-7d that may 
be captured in vitro by Th1 cells (44).
The effect of miR-155 and miR-326 on MS pathogenesis is 
cell mediated, and their role when dysregulated in plasma has 
to be further investigated. Nevertheless, EV-associated miRNAs 
display the most plausible hypothesis to explain how a subset of 
cells with altered miRNA expression could generate an overall 
dysregulated network disrupting functional homeostasis during 
relapses (model of cell non-autonomous effect in Figure  4). 
Exacerbated T cell differentiation has not yet been shown to 
correlate in a restrictive manner with relapses. However, recent 
evidence suggest that both differentiation of Th17 cells (3) and 
infiltration into the CNS by Th17 cells (58) are increased in 
relapsing patients, as compared to remitting patients. Moreover, 
one can notice that (i) upregulation of cellular miR-326 in CD4+ 
T cells is observed in relapsing patients but not in remitting 
ones (3) and (ii) upregulation of both circulating miR-326 and 
miR-155 has been assessed in relapsing patients only (5). miRNA 
transfer from the cellular to the circulating compartment may 
thus constitute a putative trigger of the switch from remission to 
a relapsing state in MS patient. Based on the EV hypothesis, it is 
worth considering miRNA transfer between:
• T cells which could favor Th1 and Th17 differentiation and 
promote their activation (proposed in Figure 4) and 
• periphery and CNS which could help to further comprehend 
the interactions between the CNS and the immune system.
The next section will focus on miRNAs as biomarkers for MS 
subtype and severity.
FiGURe 4 | Model of the cell non-autonomous effect of circulating miRNAs. Exacerbated T cell differentiation (evidence being mainly for Th17 cells) might be 
a feature of the transition from remission to relapses (3). The initial state (remission) would depict poorly differentiated T cells, whereas it ends up during relapses with 
exaggerated T cell differentiation and activation. The transition from remission to relapses also correlates with increased dysregulation of miRNAs (3, 5) that would 
drive inflammatory T cell differentiation and activation. The model of cell non-autonomous effects of miRNAs consists in the transfer through EVs of T cell 
differentiation-driving miRNAs. The cause of initial miRNA dysregulation remains unknown. Light blue, dark blue, and yellow cells depict Th1, Th17, and  
non-differentiated Th0 cells, respectively.
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Dysregulated Circulating miRNAs: 
New Biomarkers for MS?
The definitive diagnosis of MS is based on the McDonald Criteria 
to demonstrate the dissemination of CNS lesions in space and 
time in patients with symptoms suggestive of MS (59). It combines 
clinical examination (motor or sensory problems, optic neuritis, 
Lhermitt’s sign, etc.), magnetic resonance imaging (MRI) to 
detect multifocal CNS lesions and, if required, an electrophoresis 
from CSF (lumbar puncture) to reveal oligoclonal bands of IgG, 
which testify of infiltrating plasmocytes.
So, why are biomarkers for MS still arousing interest? Emerging 
biomarkers, such as circulating miRNAs, display several advanta-
geous features in comparison with previous methods:
• the possibility to support the results of the clinical diagnosis 
distinguishing MS subtypes (PPMS, RRMS, etc.) and quantify 
MS severity,
• the fact that collecting blood miRNAs and measuring their 
expression is easy, poorly invasive, and cheap,
• the robustness of circulating miRNAs which are highly stable, and
• the accuracy using composite biomarkers rather than a single one.
The chronicity in MS pathology is the cause of repetitive 
relapses causing irreversible neurodegeneration. Depending on 
MS subtypes (PPMS or RRMS), medical care will be different. 
Thus, the possibility to anticipate MS evolution is crucial. Different 
statistical methods are used to predict the diagnostic accuracy of 
a biomarker: the area under the curve (AUC) (Box 1A) and the 
experimental sensibility/specificity (Boxes  1B,C). Interestingly, 
several studies analyzed specific circulating miRNAs differen-
tially expressed according to MS subtypes (9, 18, 60).
Fenoglio and colleagues (18) found out using the AUC method 
that blood circulating miR-223 and miR-15b could discriminate 
PPMS from healthy controls with a level of diagnostic accuracy 
of 80 and 75%, respectively. It was estimated that MRI clinical 
diagnosis in the onset of patients with clinically isolated syn-
drome (CIS) had 80% diagnostic accuracy predicting MS (61). 
It remains to be determined whether monitoring miRNA levels 
in CIS patients could help improving the accuracy of MRI-based 
diagnostic. Moreover, pathologies that mimic MS prevent clini-
cal investigations from accurately predicting MS. Interestingly, 
a miRNA profiling study of the CSF of MS patients (60) (Box 1) 
reported the cut-off values of the expression of two miRNAs in 
order to discriminate MS from OND. They showed that the com-
posite use of miRNAs is promising to gain diagnostic accuracy 
differentiating MS from OND (Box  1) but also distinguishing 
RRMS from PPMS entities. It remains to be determined whether 
circulating miRNAs could be used to assess or confirm the 
diagnosis of MS subtypes or even further subdivide MS subtypes 
into smaller clusters for the customization of treatments. It is 
also of interest to understand whether the variable efficiency of 
treatments according to MS subtypes (62) correlates with changes 
in miRNA levels, since several treatments were shown to impact 
miRNA levels (63–65). Besides, miRNA levels in plasma were 
BOX 1 | Statistical tools to evaluate the relevance of a biomarker.
*The result from Haghikia et al. study of 88% was corrected because a misjudgment has been done.
How can we estimate the diagnostic accuracy of miR-633 and miR-922 to distinguish MS from other neurological diseases (OND) (60)?
First method: receiver operating characteristic (ROC) curves (A) plot sensitivity (y axis) versus 1 − specificity in (x axis). An experiment good predictor curve 
will locate between a random classifier (50% chance predicting MS or OND) and a perfect classifier (100% chance predicting MS or OND). Calculation of the area 
under the curve (AUC) gives the level of diagnostic accuracy, which corresponds to the probability that random MS patients have higher (if upregulated) or lower (if 
downregulated) miRNA levels than OND ones.
Second method: it is possible to determine a sensitivity and specificity (B) score for each cut-offs (estimated threshold of miRNA level separating MS from OND), 
thus drawing the ROC curve. The highest sensitivity and specificity score indicates the most relevant cut-off. The example in (C) represents the result of sensitivity and 
sensibility (60) (left) and the predicted results using only miR-633 (right).
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shown to correlate with the expanded disability status scale of 
MS patients (9, 18). miRNA quantification could thus be used as a 
molecular marker to access MS severity. Moreover, miRNAs prob-
ably constitute reliable biomarkers, as they were demonstrated 
more stable than mRNAs and stabilized by their vectors (EVs or 
proteins) (8). Indeed, RNase treatments, freezing–thawing cycles, 
boiling temperature exposures, and pH ranges had no effect on 
miRNA stability in plasma (8).
Although its procedure is not the most convenient, the 
analysis of CSF miRNAs from MS patients is relevant considering 
that it may better reflect the level of brain damage. The authors 
mentioned the promising future of miRNAs as biomarkers of MS 
(60) but aptly considered its limitations at the moment. Profiling 
studies are indeed performed on relatively too small samples, not 
sufficient to attest that one miRNA could be a robust biomarker. 
Moreover, patients are chosen from a confined geographic area 
with higher similarities in their susceptibility genes. Further 
investigations about whether the expression of miRNAs could 
be used to biomark MS should be performed on larger samples. 
There is a need of standardization for miRNA extraction, quan-
tification, and expression measure. Such a standardization would 
enable to compare studies and to define an optimal composite of 
miRNAs for biomarking MS.
DiSCUSSiON
There is current evidence that at least 60 circulating miRNAs 
would be dysregulated in MS patient’s blood and profiling results 
are continuously emerging. The current challenge relies on linking 
this network with the network of cellular dysregulated miRNAs. 
EVs are the most relevant miRNA carriers and could explain 
the relation between these two dysregulated networks. Both 
immune and neural cells, active actors of MS physiopathology, 
produce and receive EVs. This observation has to be considered 
besides the demonstrated implication of some cellular miRNAs, 
including miR-326 and miR-155, which were found to promote 
inflammation and demyelination.
Indeed, the hypothesis of miRNA-containing EVs raises 
the issue of a possible cell non-autonomous amplification of 
inflammation and demyelination through abnormal miRNA 
transfer. It has to be seriously considered during a period of 
relapse, in which symptom worsening is sudden. Interestingly, 
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